Development and Validation of a Novel Prognosis Model Based on a Panel of Three Immunogenic Cell Death-Related Genes for Non-Cirrhotic Hepatocellular Carcinoma

References

• Asafo-Agyei KO, Samant H. Hepatocellular carcinoma. In: StatPearls. StatPearls Publishing. Copyright © 2022, StatPearls Publishing LLC; 2022.
   Google Scholar
• Lee DH, Lee JM. Primary malignant tumours in the non-cirrhotic liver. Eur J Radiol. 2017;95:349–361. doi:10.1016/j.ejrad.2017.08.030
   PubMed Web of Science ®Google Scholar
• Su K, Huang W, Li X, et al. Evaluation of lactate dehydrogenase and alkaline phosphatase as predictive biomarkers in the prognosis of hepatocellular carcinoma and development of a new nomogram. J Hepatocell Carcinoma. 2023;10:69–79. doi:10.2147/JHC.S398632
   PubMed Web of Science ®Google Scholar
• Su K, Liu Y, Wang P, et al. Heat-shock protein 90α is a potential prognostic and predictive biomarker in hepatocellular carcinoma: a large-scale and multicenter study. Hepatol Int. 2022;16(5):1208–1219. doi:10.1007/s12072-022-10391-y
   PubMed Web of Science ®Google Scholar
• Su K, Guo L, He K, et al. PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma. Front Oncol. 2022;12:873830. doi:10.3389/fonc.2022.873830
   PubMed Web of Science ®Google Scholar
• Li H, Wu Z, Chen J, et al. External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Clin Exp Med. 2022;23(5):1537–1549. doi:10.1007/s10238-022-00972-4
   PubMed Web of Science ®Google Scholar
• Kumar M, Kumar R, Hissar SS, et al. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India. J Gastroenterol Hepatol. 2007;22(7):1104–1111. doi:10.1111/j.1440-1746.2007.04908.x
   PubMed Web of Science ®Google Scholar
• Kozbial K, Moser S, Schwarzer R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol. 2016;65(4):856–858. doi:10.1016/j.jhep.2016.06.009
   PubMed Web of Science ®Google Scholar
• Pang Q, Zhang JY, Xu XS, et al. The prognostic values of 12 cirrhosis-relative noninvasive models in patients with hepatocellular carcinoma. Scand J Clin Lab Invest. 2015;75(1):73–84. doi:10.3109/00365513.2014.981759
   PubMed Web of Science ®Google Scholar
• Mei Y, You Y, Xia J, Gong JP, Wang YB. Identifying differentially expressed microRNAs between cirrhotic and non-cirrhotic hepatocellular carcinoma and exploring their functions using bioinformatic analysis. Cell Physiol Biochem. 2018;48(4):1443–1456. doi:10.1159/000492254
   PubMedGoogle Scholar
• Xie QS, Chen ZX, Zhao YJ, Gu H, Geng XP, Liu FB. Systematic review of outcomes and meta-analysis of risk factors for prognosis after liver resection for hepatocellular carcinoma without cirrhosis. Asian J Surg. 2021;44(1):36–45. doi:10.1016/j.asjsur.2020.08.019
   PubMed Web of Science ®Google Scholar
• Perisetti A, Goyal H, Yendala R, Thandassery RB, Giorgakis E. Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: current insights and advancements. World J Gastroenterol. 2021;27(24):3466–3482. doi:10.3748/wjg.v27.i24.3466
   PubMed Web of Science ®Google Scholar
• Yen YH, Cheng YF, Wang JH, Lin CC, Wang CC, Chemin I. Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: when East meets West. PLoS One. 2021;16(1):e0244939. doi:10.1371/journal.pone.0244939
   PubMed Web of Science ®Google Scholar
• Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146(7):1691–700.e3. doi:10.1053/j.gastro.2014.02.032
   PubMed Web of Science ®Google Scholar
• Jiang Y, Chen S, Wu Y, et al. Establishment and validation of a novel prognostic model for non-virus-related hepatocellular carcinoma. Cancer Cell Int. 2022;22(1):300. doi:10.1186/s12935-022-02725-5
   PubMed Web of Science ®Google Scholar
• Liu MZ, Tang LL, Zong JF, et al. Evaluation of sixth edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement. Int J Radiat Oncol Biol Phys. 2008;70(4):1115–1123. doi:10.1016/j.ijrobp.2007.07.2353
   PubMed Web of Science ®Google Scholar
• Tharin Z, Richard C, Derangère V, et al. PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy. Sci Rep. 2023;13(1):4467. doi:10.1038/s41598-023-31593-w
   PubMed Web of Science ®Google Scholar
• Qi L, Chen F, Wang L, Yang Z, Zhang W, Li ZH. Identification of anoikis-related molecular patterns to define tumor microenvironment and predict immunotherapy response and prognosis in soft-tissue sarcoma. Front Pharmacol. 2023;14:1136184. doi:10.3389/fphar.2023.1136184
   PubMed Web of Science ®Google Scholar
• Lim SY, Shklovskaya E, Lee JH, et al. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. Nat Commun. 2023;14(1):1516. doi:10.1038/s41467-023-36979-y
   PubMed Web of Science ®Google Scholar
• Chiaravalli M, Spring A, Agostini A, Piro G, Carbone C, Tortora G. Immunogenic cell death: an emerging target in gastrointestinal cancers. Cells. 2022;11(19). doi:10.3390/cells11193033
   Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Warren S, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8(1):e000337. doi:10.1136/jitc-2019-000337
   PubMed Web of Science ®Google Scholar
• Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol. 2009;9(5):353–363. doi:10.1038/nri2545
   PubMed Web of Science ®Google Scholar
• Sprooten J, Garg AD. Type I interferons and endoplasmic reticulum stress in health and disease. Int Rev Cell Mol Biol. 2020;350:63–118. doi:10.1016/bs.ircmb.2019.10.004
   PubMed Web of Science ®Google Scholar
• Garg AD, De Ruysscher D, Agostinis P. Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: a large-scale meta-analysis. Oncoimmunology. 2016;5(2):e1069938. doi:10.1080/2162402X.2015.1069938
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Ma Y, Baracco EE, et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science. 2015;350(6263):972–978. doi:10.1126/science.aad0779
   PubMed Web of Science ®Google Scholar
• Zhao X, Yang K, Zhao R, et al. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. Biomaterials. 2016;102:187–197. doi:10.1016/j.biomaterials.2016.06.032
   PubMed Web of Science ®Google Scholar
• Meng Q, Ding B, Ma P, Lin J. Interrelation between programmed cell death and immunogenic cell death: take antitumor nanodrug as an example. Small Methods. 2023;7(5):e2201406. doi:10.1002/smtd.202201406
   PubMedGoogle Scholar
• Lu Y, Wang Y, Liu W, et al. Photothermal “nano-dot” reactivate “immune-hot” for tumor treatment via reprogramming cancer cells metabolism. Biomaterials. 2023;296:122089. doi:10.1016/j.biomaterials.2023.122089
   PubMed Web of Science ®Google Scholar
• Guo B, Qu Y, Sun Y, et al. Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative “cold” triple-negative breast cancer. Bioact Mater. 2023;25:61–72. doi:10.1016/j.bioactmat.2023.01.014
   PubMed Web of Science ®Google Scholar
• Li Y, Feng J, Wang T, et al. Construction of an immunogenic cell death-based risk score prognosis model in breast cancer. Front Genet. 2022;13:1069921. doi:10.3389/fgene.2022.1069921
   PubMed Web of Science ®Google Scholar
• Han Y, Cai Q, Xie X, Gao S, Fan X. Development and validation of prognostic index based on immunogenic cell death-related genes with melanoma. Front Oncol. 2022;12:1011046. doi:10.3389/fonc.2022.1011046
   PubMedGoogle Scholar
• Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47(4):598–607. doi:10.1016/j.jhep.2007.07.006
   PubMed Web of Science ®Google Scholar
• Xu M, Lu JH, Zhong YZ, et al. Immunogenic cell death-relevant damage-associated molecular patterns and sensing receptors in triple-negative breast cancer molecular subtypes and implications for immunotherapy. Front Oncol. 2022;12:870914. doi:10.3389/fonc.2022.870914
   PubMed Web of Science ®Google Scholar
• Langfelder P, Horvath S. Fast R functions for robust correlations and hierarchical clustering. J Stat Softw. 2012;46(11). doi:10.18637/jss.v046.i11
   PubMed Web of Science ®Google Scholar
• Ding B, Lou W, Liu J, Li R, Chen J, Fan W. In silico analysis excavates potential biomarkers by constructing miRNA-mRNA networks between non-cirrhotic HCC and cirrhotic HCC. Cancer Cell Int. 2019;19(1):186. doi:10.1186/s12935-019-0901-3
   PubMedGoogle Scholar
• Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56. doi:10.1093/annonc/mdy495
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Z, Sun J, Qian Y. Identification of HCC subtypes with different prognosis and metabolic patterns based on mitophagy. Front Cell Dev Biol. 2021;9:799507. doi:10.3389/fcell.2021.799507
   PubMed Web of Science ®Google Scholar
• Guan Q, Pan J, Ren N, Qiao C, Wei M, Li Z. Identification of novel lactate metabolism signatures and molecular subtypes for prognosis in hepatocellular carcinoma. Front Cell Dev Biol. 2022;10:960277. doi:10.3389/fcell.2022.960277
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang W, Jiang L, Chen Y. Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res. 2022;10(1):3. doi:10.1186/s40364-021-00350-4
   PubMed Web of Science ®Google Scholar
• Damaskos C, Garmpis N, Dimitroulis D, et al. Targeted therapies for hepatocellular carcinoma treatment: a new era ahead-a systematic review. Int J Mol Sci. 2022;23(22):14117. doi:10.3390/ijms232214117
   PubMed Web of Science ®Google Scholar
• Li D, Cheng X, Zheng W, Chen J. Glucosamine-6-phosphate isomerase 1 promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma. Cancer Manag Res. 2020;12:4923–4935. doi:10.2147/CMAR.S250094
   PubMed Web of Science ®Google Scholar
• Brown GC, Neher JJ. Eaten alive! Cell death by primary phagocytosis: “phagoptosis”. Trends Biochem Sci. 2012;37(8):325–332. doi:10.1016/j.tibs.2012.05.002
   PubMed Web of Science ®Google Scholar
• Mathur K, Mazhar A, Patel M, et al. Changing trends of cirrhotic and noncirrhotic hepatocellular carcinoma in the era of directly-acting antiviral agents. Clin Transl Gastroenterol. 2021;12(11):e00420. doi:10.14309/ctg.0000000000000420
   PubMed Web of Science ®Google Scholar
• Wolosker H, Kline D, Bian Y, et al. Molecularly cloned mammalian glucosamine-6-phosphate deaminase localizes to transporting epithelium and lacks oscillin activity. FASEB j. 1998;12(1):91–99. doi:10.1096/fasebj.12.1.91
   PubMed Web of Science ®Google Scholar
• Oikari S, Makkonen K, Deen AJ, et al. Hexosamine biosynthesis in keratinocytes: roles of GFAT and GNPDA enzymes in the maintenance of UDP-GlcNAc content and hyaluronan synthesis. Glycobiology. 2016;26(7):710–722. doi:10.1093/glycob/cww019
   PubMed Web of Science ®Google Scholar
• Xia R, Tang H, Shen J, et al. Prognostic value of a novel glycolysis-related gene expression signature for gastrointestinal cancer in the Asian population. Cancer Cell Int. 2021;21(1):154. doi:10.1186/s12935-021-01857-4
   PubMed Web of Science ®Google Scholar
• Hahn Y, Kim DS, Pastan IH, Lee B. Anoctamin and transmembrane channel-like proteins are evolutionarily related. Int J Mol Med. 2009;24(1):51–55. doi:10.3892/ijmm_00000205
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kobunai T, Akiyoshi T, Matsuda K, Ishihara S, Nozawa K. Prediction of response to preoperative chemoradiotherapy in rectal cancer by using reverse transcriptase polymerase chain reaction analysis of four genes. Dis Colon Rectum. 2014;57(1):23–31. doi:10.1097/01.dcr.0000437688.33795.9d
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang K, Geng L, et al. Identification of candidate diagnostic and prognostic biomarkers for pancreatic carcinoma. EBioMedicine. 2019;40:382–393. doi:10.1016/j.ebiom.2019.01.003
   PubMed Web of Science ®Google Scholar
• Guo Y, Pan WK, Wang ZW, et al. Identification of novel biomarkers for predicting prognosis and immunotherapy response in head and neck squamous cell carcinoma based on ceRNA network and immune infiltration analysis. Biomed Res Int. 2021;2021:4532438. doi:10.1155/2021/4532438
   PubMed Web of Science ®Google Scholar
• Myw N, Charsou C, Lapao A, et al. The cholesterol transport protein GRAMD1C regulates autophagy initiation and mitochondrial bioenergetics. Nat Commun. 2022;13(1):6283. doi:10.1038/s41467-022-33933-2
   PubMed Web of Science ®Google Scholar
• Hao H, Wang Z, Ren S, et al. Reduced GRAMD1C expression correlates to poor prognosis and immune infiltrates in kidney renal clear cell carcinoma. PeerJ. 2019;7:e8205. doi:10.7717/peerj.8205
   PubMed Web of Science ®Google Scholar
• Han Q, Zhao H, Jiang Y, Yin C, Zhang J. HCC-derived exosomes: critical player and target for cancer immune escape. Cells. 2019;8(6):558. doi:10.3390/cells8060558
   PubMed Web of Science ®Google Scholar
• Zhang Q, He Y, Luo N, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell. 2019;179(4):829–845.e20. doi:10.1016/j.cell.2019.10.003
   PubMed Web of Science ®Google Scholar
• Xie L, Liu M, Cai M, et al. Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma. Biomed Pharmacother. 2023;159:114254. doi:10.1016/j.biopha.2023.114254
   PubMed Web of Science ®Google Scholar
• Dehn J, Spellman S, Hurley CK, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 2019;134(12):924–934. doi:10.1182/blood.2019001212
   PubMedGoogle Scholar
• Fan WL, Shiao MS, Hui RC, et al. HLA association with drug-induced adverse reactions. J Immunol Res. 2017;2017:3186328. doi:10.1155/2017/3186328
   PubMed Web of Science ®Google Scholar
• Li CY, Park HJ, Shin J, Baik JE, Mehrara BJ, Kataru RP. Tumor-associated lymphatics upregulate MHC-II to suppress tumor-infiltrating lymphocytes. Int J Mol Sci. 2022;23(21):13470.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Bu D, Zhang Q, et al. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer. J Adv Res. 2022;51:121–134.
   PubMed Web of Science ®Google Scholar
• Hong T, Su W, Pan Y, Tian C, Lei G. Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma. Front Immunol. 2022;13:951459. doi:10.3389/fimmu.2022.951459
   PubMedGoogle Scholar
• Dai W, Shen J, Yan J, et al. Glutamine synthetase limits b-catenin-mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1. J Clin Invest. 2022;132(24). doi:10.1172/JCI161408
   Web of Science ®Google Scholar
• Allaire M, Bruix J, Korenjak M, et al. What to do about hepatocellular carcinoma: recommendations for health authorities from the International Liver Cancer Association. JHEP Rep. 2022;4(12):100578. doi:10.1016/j.jhepr.2022.100578
   PubMedGoogle Scholar
• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–491.e1. doi:10.1053/j.gastro.2018.08.065
   PubMed Web of Science ®Google Scholar
• Li H, Guo L, Su K, et al. Construction and validation of TACE therapeutic efficacy by ALR score and nomogram: a large, multicenter study. J Hepatocell Carcinoma. 2023;10:1009–1017. doi:10.2147/JHC.S414926
   PubMed Web of Science ®Google Scholar
• Su K, Shen Q, Tong J, et al. Construction and validation of a nomogram for HBV-related hepatocellular carcinoma: a large, multicenter study. Ann Hepatol. 2023;28(4):101109. doi:10.1016/j.aohep.2023.101109
   PubMed Web of Science ®Google Scholar